3'-fluoro-2',3'-dideoxy-5-methylcytidine | 177365-12-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 3'-fluoro-2',3'-dideoxy-5-methylcytidine
• 英文别名: alovudine；2',3'-Dideoxy-3'-fluoro-5-methyl-cytidine；4-amino-1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one
• CAS: 177365-12-7
• 化学式: C₁₀H₁₄FN₃O₃
• 分子量: 243.238
• InChiKey: YTMNCNXZZRCBFC-XLPZGREQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  88.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3’-脱氧-3-氟胸苷 在 吡啶 、 氨 、 溶剂黄146 、 trifluoromethanesulfonic acid anhydride 作用下， 反应 4.75h， 生成 3'-fluoro-2',3'-dideoxy-5-methylcytidine
  参考文献：
  名称：

  3'-Fluoro-2'，3'-Dideoxy-5-chlorouridine：一系列新的2'-和3'-氟化2'，3'-Dideoxynucleoside类似物中最具选择性的抗HIV-1药物。

  摘要：

  合成了一系列的2'-和3'-氟化2'，3'-双脱氧核苷和3'-叠氮基2'，3'-双脱氧核苷，并评估了其对人免疫缺陷病毒1（HIV-1）的抑制活性在MT-4细胞中复制。将3'-氟-或3'-叠氮基-2'，3'-二脱氧腺苷转化为相应的肌苷或将2'，3'-二脱氧腺苷进行8-溴化都不会增加抗HIV-1的活性。在赤型或苏型构型中引入2'-氟也没有导致母体2'，3'-二脱氧核苷的抗HIV-1活性提高。1-（2-氟-2,3-二脱氧-β-D-苏-戊呋喃糖基）胞嘧啶和1-（2-氟-2,3-二脱氧-β-D-四氢呋喃呋喃糖基）胸腺嘧啶仅具有少量活性。但是，3'-fluoro-2'，3' -dideoxyuridine（FddUrd）被证明是有效的且是相对无毒的HIV-1抑制剂。尝试制备FddUrd的5-卤代衍生物，以进一步提高其抗HIV效能和选择性。在这些5-卤代衍生物中，3'-氟-2'，3'-二脱氧-5-氯尿苷

  DOI：

  10.1021/jm00128a013

文献信息

• Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
  申请人：Mueller A. Richard

  公开号：US20050119310A1

  公开（公告）日：2005-06-02

  Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

  提供了一种治疗哺乳动物，尤其是人类肝炎病毒感染的方法和组合物。该方法包括（1）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物、二者的混合物或免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇化合物，或（2）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物、或二者的混合物以及免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇化合物。
• Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
  申请人：Mueller A. Richard

  公开号：US20050267153A1

  公开（公告）日：2005-12-01

  Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

  提供了用于治疗哺乳动物，尤其是人类乙型肝炎病毒感染的方法和组合物。该方法包括（1）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物、它们的混合物或免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚胺-D-葡萄糖醇化合物，或（2）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物或它们的混合物以及免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚胺-D-葡萄糖醇化合物。
• USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS
  申请人：——

  公开号：US20030100532A1

  公开（公告）日：2003-05-29

  Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

  提供了一种治疗哺乳动物，特别是人类肝炎病毒感染的方法和组合物。该方法包括(1)与核苷类抗病毒药物、核苷酸类抗病毒药物、两者的混合物或免疫调节/免疫刺激剂结合使用N-取代-1,5-二去氧-1,5-亚胺-D-葡萄糖醇化合物，或(2)与核苷类抗病毒药物、核苷酸类抗病毒药物、或两者的混合物以及免疫调节/免疫刺激剂结合使用N-取代-1,5-二去氧-1,5-亚胺-D-葡萄糖醇化合物。
• Peptidomimetic protease inhibitors
  申请人：Babine Edward Robert

  公开号：US20050197299A1

  公开（公告）日：2005-09-08

  The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

  本发明涉及肽类似物化合物，可用作蛋白酶抑制剂，特别是丝氨酸蛋白酶抑制剂，更特别是丙型肝炎NS3蛋白酶抑制剂；其中间体；它们的制备包括新的立体选择性过程到中间体。本发明还涉及制药组合物和使用该化合物抑制HCV蛋白酶或治疗患有HCV感染或与感染相关的生理状况的患者的方法。还提供了包括一个或多个HCV丝氨酸蛋白酶抑制剂，一个或多个表现出抗HCV活性的干扰素和/或一个或多个具有抗HCV活性和药学上可接受的载体的药物组合物，以及使用该组合物治疗或预防患者的HCV感染的方法。本发明还涉及用于治疗或预防患者HCV感染的工具包或药品包装。
• Chiral intermediates for the preparation of peptidomimetic protease inhibitors
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1876173A1

  公开（公告）日：2008-01-09

  The present application relates to intermediate compounds according to formula (24,25,26 and 27) for the preparation of peptidomimetic compounds which are useful as protease inhibitors: wherein is optionally substituted fused arylcycloalkyl; R11 is -CO2R13; R12 is iminic glycinimide derivative adduct; and R13 is acid protecting group or optionally substituted aliphatic group. wherein: R15 is optionally substituted aliphatic group; and R16 is acid protecting group, optionally substituted aryl, or optionally substituted aliphatic group. wherein: p° is amide protecting group;

  本申请涉及中间化合物，其化学式为（24、25、26和27），用于制备肽类模拟化合物，这些化合物可用作蛋白酶抑制剂： 其中，X是可选取代的融合芳基环烷基；R11是-CO2R13；R12是亚胺基甘氨酰亚胺衍生物加合物；R13是酸保护基或可选取代的脂肪基。 其中，R15是可选取代的脂肪基；R16是酸保护基、可选取代的芳基或可选取代的脂肪基。 其中，p°是酰胺保护基。